EPISODE · Feb 21, 2012 · 8 MIN
The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia
from Journal of Clinical Oncology (JCO) Podcast
This podcast reports on a phase I/II trial investigating novel anti-CD22, moxetumomab pasudotox, in the treatment of patients with refractory hairy cell leukemia, which demonstrated responses in the majority of patients at all dose levels.
Embed this episode
NOW PLAYING
The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia
0:00
8:16
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Journal of Clinical Oncology (JCO) Podcast?
This episode is 8 minutes long.
When was this Journal of Clinical Oncology (JCO) Podcast episode published?
This episode was published on February 21, 2012.
Can I download this Journal of Clinical Oncology (JCO) Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!